Research · Emerging confidence
Alzheimer's early-stage protocols
Early-stage cognitive decline is the most credible long-horizon indication expansion. Small studies show cerebral perfusion improvement, and a larger RCT is enrolling — but this remains a research-watch item rather than a 2026 revenue plan.
Momentum
58
30d change
+6%
90d change
+22%
Confidence
Emerging
What's driving it
- Perfusion imaging endpoints improving in small cohorts
- Larger multi-site RCT actively enrolling
- Caregiver-driven inquiry volume rising independently of physician referral
Risks and counter-signals
- Sample sizes too small to support marketing claims
- Ethical exposure when marketing to cognitively impaired patients
- Long timeline to any coverage decision
Recommended actions
- Track the enrolling RCT and register interest as a referral site
- Draft a conservative caregiver FAQ that sets realistic expectations
- Do not add capacity for this indication yet
Signal panel
- Active trials
- 9
- Publications 90d
- 6
- Coverage outlook
- None near-term
- Evidence strength
- Emerging